(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Insider facts of Viable Advertising: Building a Positive Brand Picture - 2Vote In favor of Your Favored Sort Of Bevarage
- 3Manual for Instructive Application for Youngsters
- 4Building an Individual Brand: Illustrations from Forces to be reckoned with
- 5Instructions to Grasp the Innovation Behind 5G Pinnacles\
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Instructions to Plan for Your Teeth Substitution Methodology
- Must-See Attractions in Washington, D.C.
- WHO issues guidance on GLP-1 drugs for obesity
- Overlooked infertility care should be part of national health services, says WHO
- Sports Shoes of 2024: Upgrade Execution and Solace
- 5 Arising Vocations in Sustainable power
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
